Celebrity Inventors
Actress Jamie Lee Curtis is a patented inventor - she created a diaper equipped with a premoistened baby wipe. And that's no act!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7700798 | Erogorgiaene congeners and methods and intermediates useful in the preparation of same Disclosed are compounds having the formula: wherein R21 is an alkyl, aryl, alkoxy, hydroxy, or amino group or a halogen atom; wherein R2 is hydrogen or an alkyl, aryl, alkoxy, or amino group; wherein R... | 04/20/2010 |
| RE41151 | Protected forms of pharmacologically active agents and uses thereof In accordance with the present invention, there are provided normal modified forms of nonsteroidal anti-inflammatory drugs. Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provide the therapeutic benefits of NSAIDs whi... | 02/23/2010 |
| 7470807 | Substituted arylalkanoic acid derivatives and use thereof A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independe... | 12/30/2008 |
| 7413782 | Polymerizing binaphthalene derivatives Provided are a polymerizing liquid-crystalline compound of formula (1). In formula (1), Q1 to Q4 each independently represent a formula (2), a hydrogen atom, a halogen atom, an alkyl group or the like;... | 08/19/2008 |
| 7371888 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents Compounds having a formula: or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders. ... | 05/13/2008 |
| 7358383 | Polyphenol proteasome inhibitors, synthesis, and methods of use The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in m... | 04/15/2008 |
| 7345189 | Process for the preparation of adapalene A process for the preparation of a compound of formula (I), or a salt thereof wherein R is H, C1-C8 alkyl, aryl or aryl-C1-C8 alkyl; comprising the reaction between a compound of ... | 03/18/2008 |
| 7268148 | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying ... | 09/11/2007 |
| 7169325 | Liquid crystalline compound, liquid crystalline composition and retardation film To provide a liquid crystalline compound capable of exhibiting a biaxial liquid crystal phase, provide a trifunctional or greater functional polymerizable liquid crystalline compound having polymerizable groups, and also to provide a liquid crystalline composition a... | 01/30/2007 |
| 7166726 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity Disclosed herein are compounds of the formula wherein R1 is independently H or alkyl of 1 to 6 carbons; R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br... | 01/23/2007 |
| 7163918 | Iodothyronine compositions The present invention relates to compositions comprising thyroxine (T4) and triiodothyronine (T3). More specifically, the invention relates to thyroxine (T4) and triiodothyronine (T3) compositions that include a peptide carrier and thyroxine (T4) and triiodothyronin... | 01/16/2007 |
| 7153548 | Compound, retardation plate and method for forming optically anisotropic layer A retardation plate having a high film strength and having an optical property is provided by using a biaxial liquid crystal compound, in which the direction having a minimum refractive index of the optically anisotropic thin layer almost coincides with the normal d... | 12/26/2006 |
| 7115728 | Human peroxisome proliferator activated receptor γ The present invention relates to a novel human peroxisome proliferator activated receptor, hPPARγ. hPPARγ differs from the mouse peroxisome proliferator activated receptor γ in the nucleotide sequence and the amino acid sequence. The invention provides isolated, ... | 10/03/2006 |
| 7098025 | Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor This invention relates to the isolation and cloning of the promoter and other control regions of human PPARγ gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level o... | 08/29/2006 |
| 7094919 | Preparation of substituted aromatic carboxylic acid esters Methods for preparing substituted aromatic carboxylic acid esters are described. In particular, the invention relates a method for preparing a nitro-substituted aromatic carboxylic acid ester: Additionally the inventio... | 08/22/2006 |
| 7074826 | R-NSAID esters and their use The present invention concerns esters of R-enantiomers of a non-steroidal anti-inflammatory drug, which is substantially free from the S-enantiomer. The compounds of the invention may be used in treating a disease or illness in a mammal. To this end, a composition c... | 07/11/2006 |
| 7060708 | Active agent delivery systems and methods for protecting and administering active agents The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions... | 06/13/2006 |
| 7053123 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders (E)-Styryl benzylsulfones useful as antiproliferative agents, including, for example, anticancer agents, are provided according to formula I: wherein: R1 is selected from the group consisting of halogen, C1–C6 alkoxy, nitro, phosphonato, amino, sulfamyl... | 05/30/2006 |
| 7041845 | Process for preparing optically active dihydropyrones The invention relates to a process for preparing optically active 5-hydroxy-3-ketoesters of formula A1 or A2, or one of the tautomers thereof, the use thereof for preparing optically active dihydropyron... | 05/09/2006 |
| 7038070 | Preparation of preparing substituted indanones A process for the preparation of indanones of the formula II from indanones of the formula I or of indanones of the formula IIa from indanones of the formula Ia comprises reacting an indanone of the formula I or Ia wit... | 05/02/2006 |
| 7019034 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXRβ retinoid receptors than as agonists of RXRα or RXRγ retinoid receptors. The treatment reduces serum glucose and triglyceride l... | 03/28/2006 |
| 7001926 | Tubulin binding agents and corresponding prodrug constructs A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin... | 02/21/2006 |
| 6942980 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities Methods of characterizing and identifying negative hormones of nuclear receptors. Also disclosed are methods of making modulators of retinoid nuclear receptor transactivation activity, assays for agonists, antagonists, and negative hormones of the RAR receptor, and ... | 09/13/2005 |
| 6939988 | Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them Novel β-aryl-α-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses. ... | 09/06/2005 |
| 6936636 | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity Compounds of the formula: where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects... | 08/30/2005 |
| 6927300 | Process for the preparation of Latanoprost Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process. ... | 08/09/2005 |
| 6905739 | Optically active materials A compound is of formula (I), in which: A1 to A4, E1 and E2 each independently represent hydrogen or an optionally-substituted hydrocarbon group; B1 and B2 each independently represent a single bond, ... | 06/14/2005 |
| 6891072 | Process for production of dimers or aromatic monohydroxyl compounds The present invention provides a method for preparing dimer of a monohydroxy aromatic compound. In the method of the present invention, oxidative coupling reaction of a monohydroxy aromatic compound represented by formula [I]: Ar—OH [I] | 05/10/2005 |
| 6887896 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity Compounds of the formula where the variations have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasin... | 05/03/2005 |
| 6884820 | 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxin... | 04/26/2005 |
| 6878842 | Process for the enantioselective synthesis of propargyl alcohol derivatives of R configuration from the racemic mixtures thereof The invention relates to a novel process for synthesizing organic compounds of general formula (I): said process may be carried out on an industrial scale and makes it possible to obtain from a... | 04/12/2005 |
| 6867320 | Substituted phenylalkanoic acid derivatives and use thereof A compound represented by the formula (I) or a salt thereof: wherein n represents an integer of 1 to 3, R represents an alkyl group having 3 to 8 carbon atoms, a group represented by the following formula: R1 | 03/15/2005 |
| 6849742 | Binaphthol derivative and process for producing the same The present invention provides a binaphthol compound represented by formula [1]: and a salt thereof. The binaphthol compound of the present invention is useful for manufacturing antiseptic compounds or chiral catalysts... | 02/01/2005 |
| 6846890 | Norbornene derivative and norbornene polymer obtained therefrom through ring opening polymerization A novel norbornene derivative represented by a general formula (1m) shown below is provided. By conducting a ring opening polymerization of this norbornene derivative, or by performing a subsequent hydrogenation following the ring opening polymerization, a ring open... | 01/25/2005 |
| 6838574 | Dicarba-closo-dodecarborane derivatives A medicament comprising as an active ingredient a compound or a physiologically acceptable salt thereof represented by general formula (I): wherein R1 represents a dicarba-closo-dodecaboran-yl which may be s... | 01/04/2005 |
| 6835427 | Optically active compound and liquid crystal composition containing the compound An optically active compound containing 5,5′,6,6′,7,7′,8,8′-octahydro-1,1′-bi-2-naphthol of the general formula (1) as an asymmetric source, wherein n is an integer of 1 to 10, Y is a hydrogen atom, an alkyl gr... | 12/28/2004 |
| 6825233 | Compounds having retinoid-like activity There are provided compounds represented by the formula I or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, wherein the various substituents are as defined. Also inc... | 11/30/2004 |
| 6800658 | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation The present invention provides substituted 3,3-diphenyl indanone, indane and indole compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell prolifera... | 10/05/2004 |
| 6790864 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly don... | 09/14/2004 |
| 6759547 | 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine ... | 07/06/2004 |
